SIMILAR PATTERNS OF AMINO ACIDS FOR 3AOX_A_EMHA901_1

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1k2p	TYROSINE-PROTEIN KINASE BTK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 428 LYS A 430 VAL A 458 MET A 477 GLY A 480 LEU A 528	None	0.53A	3aoxA-1k2pA: 28.3	3aoxA-1k2pA: 33.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	ALA A 220 LYS A 222 VAL A 249 MET A 269 GLY A 272 LEU A 321	None	0.50A	3aoxA-1k9aA: 27.1	3aoxA-1k9aA: 27.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 267 ALA A 288 VAL A 318 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-3.4A) P16 A 2 ( 4.7A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.74A	3aoxA-1opkA: 30.4	3aoxA-1opkA: 27.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 78 ALA A 99 LYS A 101 VAL A 131 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-3.6A) ATP A 535 ( 2.5A) 5EA A1001 (-4.5A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.83A	3aoxA-1s9iA: 21.7	3aoxA-1s9iA: 25.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1snx	TYROSINE-PROTEIN KINASE ITK/TSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 389 LYS A 391 VAL A 419 MET A 438 GLY A 441 LEU A 489	None	0.58A	3aoxA-1snxA: 22.6	3aoxA-1snxA: 35.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1zlt	SERINE/THREONINE-PRO TEIN KINASE CHK1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 15 ALA A 36 LYS A 38 VAL A 68 LEU A 84 GLY A 90 LEU A 137	HYM A 400 (-4.2A) HYM A 400 (-3.5A) HYM A 400 (-3.2A) HYM A 400 (-4.8A) HYM A 400 (-4.2A) None HYM A 400 (-4.5A)	0.66A	3aoxA-1zltA: 20.9	3aoxA-1zltA: 24.15
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU X 17 ALA X 37 VAL X 67 MET X 85 GLY X 88 LEU X 137	STU X 902 (-3.8A) STU X 902 (-3.1A) None None STU X 902 (-3.5A) STU X 902 (-4.4A)	0.66A	3aoxA-2dq7X: 30.4	3aoxA-2dq7X: 35.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 19 ALA A 40 LYS A 42 LEU A 95 MET A 96 LEU A 144	ADP A 500 (-4.3A) ADP A 500 ( 3.7A) ADP A 500 (-2.9A) ADP A 500 ( 4.9A) None ADP A 500 (-4.3A)	0.60A	3aoxA-2f9gA: 21.9	3aoxA-2f9gA: 24.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 ALA A 293 LYS A 295 VAL A 323 MET A 341 GLY A 344 LEU A 393	H8H A 534 (-3.8A) H8H A 534 (-3.2A) H8H A 534 (-3.7A) None None H8H A 534 (-3.3A) H8H A 534 (-4.5A)	0.72A	3aoxA-2h8hA: 29.1	3aoxA-2h8hA: 25.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 273 ALA A 293 VAL A 323 MET A 341 GLY A 344 LEU A 393	QUE A 1 (-3.9A) QUE A 1 (-3.5A) None None QUE A 1 (-3.0A) QUE A 1 (-4.4A)	0.62A	3aoxA-2hckA: 28.2	3aoxA-2hckA: 29.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 ALA A 271 LYS A 273 VAL A 301 MET A 319 GLY A 322 LEU A 371	1BM A 499 ( 3.7A) 1BM A 499 (-3.6A) 1BM A 499 (-3.8A) None None 1BM A 499 (-3.5A) 1BM A 499 (-4.4A)	0.59A	3aoxA-2hk5A: 30.8	3aoxA-2hk5A: 33.92
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 248 ALA A 269 LYS A 271 VAL A 299 MET A 318 GLY A 321 LEU A 370	GIN A 600 ( 4.6A) GIN A 600 (-3.1A) GIN A 600 (-3.6A) GIN A 600 (-4.6A) None None GIN A 600 (-4.7A)	0.77A	3aoxA-2hz0A: 30.0	3aoxA-2hz0A: 35.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2j0j	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF00373 (FERM_M) PF07714 (Pkinase_Tyr)	6	ARG A 426 ALA A 452 VAL A 484 LEU A 501 GLY A 505 LEU A 553	None 4ST A1687 (-3.3A) None 4ST A1687 (-4.3A) 4ST A1687 (-3.2A) 4ST A1687 (-4.4A)	0.84A	3aoxA-2j0jA: 32.0	3aoxA-2j0jA: 20.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2jkm	FOCAL ADHESION KINASE 1 (Gallus gallus)	PF07714 (Pkinase_Tyr)	6	ALA A 452 LYS A 454 VAL A 484 LEU A 501 GLY A 505 LEU A 553	BII A1687 (-3.5A) BII A1687 (-2.9A) None BII A1687 (-4.4A) BII A1687 (-3.6A) BII A1687 (-4.2A)	0.68A	3aoxA-2jkmA: 31.1	3aoxA-2jkmA: 35.89
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 ALA A 271 LYS A 273 VAL A 301 MET A 319 GLY A 322 LEU A 371	None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 3.4A) None 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A)	0.93A	3aoxA-2og8A: 29.4	3aoxA-2og8A: 40.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2ogv	MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 588 ALA A 614 LYS A 616 VAL A 647 GLY A 669 LEU A 785	None	0.69A	3aoxA-2ogvA: 20.4	3aoxA-2ogvA: 36.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 344 ALA A 367 LYS A 369 VAL A 399 GLY A 419 LEU A 468	ANP A 615 (-4.4A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) None None ANP A 615 (-4.7A)	0.88A	3aoxA-2ozoA: 24.8	3aoxA-2ozoA: 24.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 344 ALA A 367 LYS A 369 VAL A 399 GLY A 420 LEU A 468	ANP A 615 (-4.4A) ANP A 615 (-3.3A) ANP A 615 (-3.1A) None ANP A 615 ( 3.9A) ANP A 615 (-4.7A)	0.65A	3aoxA-2ozoA: 24.8	3aoxA-2ozoA: 24.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	6	LEU A 25 ALA A 46 LEU A 105 MET A 106 GLY A 109 LEU A 156	ATP A 381 ( 4.3A) ATP A 381 (-3.5A) None None None ATP A 381 ( 4.8A)	0.44A	3aoxA-2phkA: 22.2	3aoxA-2phkA: 23.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2pmo	SER/THR PROTEIN KINASE (Plasmodium falciparum)	PF00069 (Pkinase)	6	ARG X 32 LEU X 34 ALA X 53 LYS X 55 MET X 120 LEU X 179	None HMD X 400 ( 4.3A) HMD X 400 (-3.5A) HMD X 400 (-4.2A) None HMD X 400 (-4.7A)	0.86A	3aoxA-2pmoX: 21.4	3aoxA-2pmoX: 24.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	ALA B 67 LYS B 69 VAL B 98 MET B 117 GLY B 120 LEU B 171	None	0.55A	3aoxA-2qkwB: 17.6	3aoxA-2qkwB: 28.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 724 ALA A 749 LYS A 751 VAL A 781 LEU A 798 MET A 799 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 (-3.3A) GW7 A 1 (-3.9A) GW7 A 1 ( 4.7A) GW7 A 1 (-4.5A) None GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.98A	3aoxA-2r4bA: 23.4	3aoxA-2r4bA: 32.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 226 ALA A 247 LEU A 301 LEU A 303 MET A 304 GLY A 307 LEU A 354	XK9 A1511 (-3.8A) XK9 A1511 ( 4.1A) XK9 A1511 (-4.6A) XK9 A1511 (-4.1A) None XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A)	0.60A	3aoxA-2xk9A: 12.8	3aoxA-2xk9A: 25.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 68 ALA A 92 LYS A 94 VAL A 125 LEU A 141 GLY A 147	STU A 1 (-3.8A) STU A 1 (-3.3A) STU A 1 (-2.8A) None STU A 1 ( 4.6A) STU A 1 ( 3.9A)	0.85A	3aoxA-2z7rA: 21.3	3aoxA-2z7rA: 24.66
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2z7r	RIBOSOMAL PROTEIN S6 KINASE ALPHA-1 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 68 ALA A 92 VAL A 125 LEU A 141 GLY A 147 LEU A 194	STU A 1 (-3.8A) STU A 1 (-3.3A) None STU A 1 ( 4.6A) STU A 1 ( 3.9A) STU A 1 (-4.6A)	0.87A	3aoxA-2z7rA: 21.3	3aoxA-2z7rA: 24.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	ARG A1000 LEU A1002 ALA A1028 LYS A1030 VAL A1060 LEU A1078 MET A1079 GLY A1082	None S91 A 1 ( 4.1A) S91 A 1 (-3.2A) S91 A 1 ( 4.2A) None S91 A 1 (-4.7A) None S91 A 1 (-3.3A)	0.66A	3aoxA-2z8cA: 29.6	3aoxA-2z8cA: 44.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	7	LEU A 253 ALA A 273 LYS A 275 VAL A 303 MET A 322 GLY A 325 LEU A 374	None	0.38A	3aoxA-2zv7A: 31.4	3aoxA-2zv7A: 34.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 220 LYS A 222 VAL A 249 MET A 269 GLY A 272 LEU A 321	None	0.50A	3aoxA-3d7uA: 27.1	3aoxA-3d7uA: 33.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3fme	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 59 ALA A 80 VAL A 113 LEU A 131 MET A 132 LEU A 186	STU A 1 (-3.8A) STU A 1 (-3.4A) None STU A 1 (-4.6A) None STU A 1 (-4.4A)	0.72A	3aoxA-3fmeA: 21.0	3aoxA-3fmeA: 26.37
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3fzp	PROTEIN TYROSINE KINASE 2 BETA (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 431 ALA A 455 LYS A 457 VAL A 487 LEU A 504 GLY A 508 LEU A 556	AGS A 999 ( 4.4A) AGS A 999 (-3.6A) AGS A 999 (-2.5A) None AGS A 999 (-4.4A) None AGS A 999 (-4.5A)	0.99A	3aoxA-3fzpA: 30.9	3aoxA-3fzpA: 35.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3i6u	SERINE/THREONINE-PRO TEIN KINASE CHK2 (Homo sapiens)	PF00069 (Pkinase) PF00498 (FHA)	7	LEU A 226 ALA A 247 LEU A 301 LEU A 303 MET A 304 GLY A 307 LEU A 354	None	0.85A	3aoxA-3i6uA: 21.3	3aoxA-3i6uA: 23.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lj0	SERINE/THREONINE-PRO TEIN KINASE/ENDORIBONUCLE ASE IRE1 (Saccharomyces cerevisiae)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A)	6	LEU A 680 ALA A 700 LYS A 702 LEU A 745 LEU A 747 LEU A 804	ADP A2101 ( 4.1A) ADP A2101 (-3.5A) ADP A2101 (-2.7A) ADP A2101 ( 4.4A) None ADP A2101 (-4.4A)	0.63A	3aoxA-3lj0A: 22.6	3aoxA-3lj0A: 22.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lw0	INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ARG A1003 LEU A1005 ALA A1031 VAL A1063 LEU A1081 MET A1082 GLY A1085	None None None CCX A 1 (-4.1A) None None None	0.54A	3aoxA-3lw0A: 29.4	3aoxA-3lw0A: 39.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nuu	PKB-LIKE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 88 ALA A 109 LYS A 111 LEU A 159 GLY A 165 LEU A 212	JOZ A 361 (-4.1A) JOZ A 361 (-3.4A) SO4 A 5 (-2.8A) JOZ A 361 (-4.0A) None None	0.81A	3aoxA-3nuuA: 23.2	3aoxA-3nuuA: 23.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ALA A 213 VAL A 247 LEU A 263 LEU A 265 MET A 266 GLY A 268 LEU A 318	AMP A 577 (-3.4A) None AMP A 577 ( 4.7A) AMP A 577 ( 4.9A) None None AMP A 577 (-4.8A)	1.11A	3aoxA-3nyoA: 22.1	3aoxA-3nyoA: 21.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ARG A 190 LEU A 192 ALA A 213 LYS A 215 LEU A 263 GLY A 269 LEU A 318	None AMP A 577 ( 4.3A) AMP A 577 (-3.4A) AMP A 577 (-2.8A) AMP A 577 ( 4.7A) None AMP A 577 (-4.8A)	1.18A	3aoxA-3nyoA: 22.1	3aoxA-3nyoA: 21.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	9	LEU A 192 ALA A 213 LYS A 215 VAL A 247 LEU A 263 LEU A 265 MET A 266 GLY A 269 LEU A 318	AMP A 577 ( 4.3A) AMP A 577 (-3.4A) AMP A 577 (-2.8A) None AMP A 577 ( 4.7A) AMP A 577 ( 4.9A) None None AMP A 577 (-4.8A)	0.60A	3aoxA-3nyoA: 22.1	3aoxA-3nyoA: 21.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 726 ALA A 751 LEU A 800 MET A 801 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-3.1A) 03Q A 1 (-4.6A) None 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.65A	3aoxA-3pp0A: 30.5	3aoxA-3pp0A: 33.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3sxs	CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 423 ALA A 443 LYS A 445 VAL A 473 GLY A 495 LEU A 543	PP2 A 1 (-4.1A) PP2 A 1 (-3.2A) PP2 A 1 (-4.5A) None PP2 A 1 ( 4.2A) PP2 A 1 (-4.6A)	0.72A	3aoxA-3sxsA: 24.9	3aoxA-3sxsA: 33.62
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ARG A 542 LEU A 544 ALA A 570 VAL A 601 MET A 620 GLY A 623 LEU A 686	None 0F4 A 902 ( 4.2A) 0F4 A 902 (-3.2A) None None 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.64A	3aoxA-3v5qA: 30.6	3aoxA-3v5qA: 37.68
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 59 ALA A 80 VAL A 113 LEU A 131 MET A 132 LEU A 186	None ANK A 401 (-3.0A) None None None ANK A 401 ( 4.9A)	0.64A	3aoxA-3vn9A: 21.5	3aoxA-3vn9A: 26.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3w18	AURORA KINASE A (Homo sapiens)	PF00069 (Pkinase)	7	ARG A 137 LEU A 139 ALA A 160 LYS A 162 LEU A 210 GLY A 216 LEU A 263	N13 A 501 ( 4.6A) N13 A 501 (-3.7A) N13 A 501 ( 4.1A) N13 A 501 (-2.9A) N13 A 501 ( 4.8A) N13 A 501 (-3.5A) N13 A 501 (-4.5A)	1.17A	3aoxA-3w18A: 21.6	3aoxA-3w18A: 24.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 75 ALA A 96 LYS A 98 VAL A 128 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 (-3.2A) ANP A 401 (-2.7A) CHU A 403 (-4.2A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.65A	3aoxA-3wigA: 22.8	3aoxA-3wigA: 24.33
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A1978 LEU A2026 LEU A2028 MET A2029 GLY A2031 LEU A2086	VGH A3000 (-3.4A) VGH A3000 ( 4.2A) VGH A3000 ( 4.8A) None None VGH A3000 (-4.3A)	0.90A	3aoxA-3zbfA: 33.8	3aoxA-3zbfA: 45.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1951 ALA A1978 LEU A2026 LEU A2028 MET A2029 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.2A) VGH A3000 ( 4.8A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.44A	3aoxA-3zbfA: 33.8	3aoxA-3zbfA: 45.64
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1951 ALA A1978 LYS A1980 LEU A2026 LEU A2028 GLY A2032 LEU A2086	VGH A3000 ( 4.4A) VGH A3000 (-3.4A) VGH A3000 ( 4.7A) VGH A3000 ( 4.2A) VGH A3000 ( 4.8A) VGH A3000 (-3.5A) VGH A3000 (-4.3A)	0.54A	3aoxA-3zbfA: 33.8	3aoxA-3zbfA: 45.64
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4a4l	SERINE/THREONINE-PRO TEIN KINASE PLK1 (Homo sapiens)	PF00069 (Pkinase)	7	ARG A 57 LEU A 59 ALA A 80 LYS A 82 VAL A 114 LEU A 130 LEU A 132	939 A1331 (-3.9A) 939 A1331 (-3.7A) 939 A1331 (-3.5A) 939 A1331 (-2.6A) None 939 A1331 ( 4.7A) 939 A1331 (-4.4A)	0.76A	3aoxA-4a4lA: 23.5	3aoxA-4a4lA: 25.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4agd	VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 840 ALA A 866 LYS A 868 VAL A 899 GLY A 922 LEU A1035	B49 A2000 (-3.7A) B49 A2000 (-3.5A) B49 A2000 (-3.0A) B49 A2000 ( 4.6A) B49 A2000 ( 3.7A) B49 A2000 (-4.5A)	0.78A	3aoxA-4agdA: 29.6	3aoxA-4agdA: 33.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ARG A 558 LEU A 560 ALA A 586 VAL A 617 MET A 636 GLY A 639 LEU A 699	None LTI A1839 ( 4.2A) LTI A1839 (-3.3A) None None LTI A1839 (-3.4A) LTI A1839 (-4.2A)	0.64A	3aoxA-4at3A: 30.7	3aoxA-4at3A: 36.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4b6l	SERINE/THREONINE-PRO TEIN KINASE PLK3 (Homo sapiens)	PF00069 (Pkinase)	7	ARG A 66 LEU A 68 ALA A 89 LYS A 91 VAL A 123 LEU A 139 LEU A 141	9ZP A1333 (-3.3A) 9ZP A1333 (-3.9A) 9ZP A1333 (-3.5A) None 9ZP A1333 (-4.4A) 9ZP A1333 (-3.8A) 9ZP A1333 (-4.7A)	0.72A	3aoxA-4b6lA: 23.5	3aoxA-4b6lA: 24.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4e93	TYROSINE-PROTEIN KINASE FES/FPS (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	ALA A 588 LYS A 590 VAL A 620 LEU A 638 GLY A 642 LEU A 690	GUI A 901 (-3.4A) GUI A 901 (-2.8A) None GUI A 901 (-4.4A) GUI A 901 (-3.5A) GUI A 901 (-4.3A)	0.53A	3aoxA-4e93A: 32.9	3aoxA-4e93A: 34.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 515 ALA A 541 VAL A 572 MET A 591 GLY A 594 LEU A 656	None	0.49A	3aoxA-4f0iA: 25.2	3aoxA-4f0iA: 37.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 377 ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501	0SB A 701 ( 3.9A) 0SB A 701 (-3.3A) 0SB A 701 ( 4.8A) None 0SB A 701 (-3.5A) 0SB A 701 (-4.4A)	0.43A	3aoxA-4f4pA: 24.8	3aoxA-4f4pA: 32.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 377 ALA A 400 LYS A 402 VAL A 433 GLY A 454 LEU A 501	ANP A 701 ( 4.6A) ANP A 701 (-3.3A) ANP A 701 (-2.7A) ANP A 701 (-4.8A) ANP A 701 ( 4.2A) ANP A 701 (-4.5A)	0.60A	3aoxA-4fl3A: 20.4	3aoxA-4fl3A: 21.99
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	ALA A1148 VAL A1180 LEU A1196 LEU A1198 MET A1199 GLY A1201 LEU A1256	0UV A1501 (-3.4A) 0UV A1501 ( 4.9A) 0UV A1501 (-3.7A) 0UV A1501 ( 4.8A) None 0UV A1501 (-4.4A) 0UV A1501 (-4.6A)	0.97A	3aoxA-4fodA: 48.3	3aoxA-4fodA: 99.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	9	LEU A1122 ALA A1148 LYS A1150 VAL A1180 LEU A1196 LEU A1198 MET A1199 GLY A1202 LEU A1256	0UV A1501 (-3.8A) 0UV A1501 (-3.4A) 0UV A1501 (-3.7A) 0UV A1501 ( 4.9A) 0UV A1501 (-3.7A) 0UV A1501 ( 4.8A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A)	0.42A	3aoxA-4fodA: 48.3	3aoxA-4fodA: 99.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hzs	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14604 (SH3_9)	6	LEU A 132 ALA A 156 LYS A 158 LEU A 207 GLY A 211 LEU A 259	None	0.66A	3aoxA-4hzsA: 19.4	3aoxA-4hzsA: 32.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 132 ALA A 156 LYS A 158 LEU A 207 GLY A 211 LEU A 259	1G0 A 401 ( 4.5A) 1G0 A 401 (-3.6A) 1G0 A 401 (-3.7A) 1G0 A 401 ( 4.9A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A)	0.56A	3aoxA-4id7A: 30.2	3aoxA-4id7A: 33.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 406 ALA A 427 LYS A 429 VAL A 453 LEU A 471 LEU A 522	T28 A 701 (-3.8A) T28 A 701 (-3.0A) T28 A 701 ( 3.8A) None T28 A 701 ( 4.8A) T28 A 701 (-3.9A)	0.84A	3aoxA-4idtA: 22.7	3aoxA-4idtA: 24.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4idt	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 406 ALA A 427 VAL A 453 LEU A 471 GLY A 475 LEU A 522	T28 A 701 (-3.8A) T28 A 701 (-3.0A) None T28 A 701 ( 4.8A) T28 A 701 ( 3.0A) T28 A 701 (-3.9A)	0.87A	3aoxA-4idtA: 22.7	3aoxA-4idtA: 24.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4j7b	POLO-LIKE KINASE (Danio rerio)	PF00069 (Pkinase)	6	ARG A 43 LEU A 45 ALA A 66 LYS A 68 VAL A 100 LEU A 116	None	0.68A	3aoxA-4j7bA: 23.3	3aoxA-4j7bA: 24.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 ALA A 293 LYS A 295 VAL A 323 MET A 341 GLY A 344 LEU A 393	0J9 A 601 (-4.0A) 0J9 A 601 (-3.3A) 0J9 A 601 ( 4.7A) None None 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A)	0.63A	3aoxA-4k11A: 29.0	3aoxA-4k11A: 28.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 33 ALA A 54 LYS A 56 VAL A 83 GLY A 105 LEU A 153	GOL A 404 ( 3.6A) GOL A 404 ( 3.1A) GOL A 403 ( 4.6A) GOL A 403 (-4.1A) GOL A 404 (-3.6A) GOL A 403 ( 4.4A)	0.54A	3aoxA-4lg4A: 18.0	3aoxA-4lg4A: 25.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	7	LEU A 273 ALA A 293 LYS A 295 VAL A 323 MET A 341 GLY A 344 LEU A 393	VGG A 601 (-3.2A) VGG A 601 (-3.5A) VGG A 601 (-3.8A) VGG A 601 ( 4.8A) None VGG A 601 ( 3.2A) VGG A 601 (-4.5A)	0.42A	3aoxA-4lggA: 28.9	3aoxA-4lggA: 33.33
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	8	ALA A 218 LYS A 220 VAL A 255 LEU A 271 LEU A 273 MET A 274 GLY A 276 LEU A 324	29X A 702 (-3.1A) 29X A 702 (-3.6A) 29X A 702 (-4.8A) 29X A 702 ( 4.7A) 29X A 702 (-4.6A) None None 29X A 702 (-4.6A)	0.88A	3aoxA-4mk0A: 21.5	3aoxA-4mk0A: 19.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4mk0	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00169 (PH) PF00615 (RGS)	8	ALA A 218 LYS A 220 VAL A 255 LEU A 271 LEU A 273 MET A 274 GLY A 277 LEU A 324	29X A 702 (-3.1A) 29X A 702 (-3.6A) 29X A 702 (-4.8A) 29X A 702 ( 4.7A) 29X A 702 (-4.6A) None None 29X A 702 (-4.6A)	0.76A	3aoxA-4mk0A: 21.5	3aoxA-4mk0A: 19.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o1o	RIBONUCLEASE L (Sus scrofa)	PF00069 (Pkinase) PF06479 (Ribonuc_2-5A) PF12796 (Ank_2) PF13857 (Ank_5)	6	ALA A 388 LYS A 390 VAL A 416 LEU A 432 LEU A 434 LEU A 489	None	0.59A	3aoxA-4o1oA: 16.3	3aoxA-4o1oA: 17.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o38	CYCLIN-G-ASSOCIATED KINASE (Homo sapiens)	PF00069 (Pkinase)	8	ARG A 44 LEU A 46 ALA A 67 LYS A 69 VAL A 99 LEU A 125 GLY A 128 LEU A 180	None SIN A 401 ( 3.9A) SIN A 401 ( 3.7A) None None SIN A 401 ( 4.8A) SIN A 401 (-3.5A) SIN A 401 ( 4.5A)	0.73A	3aoxA-4o38A: 20.2	3aoxA-4o38A: 24.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4rt7	RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 616 ALA A 642 LYS A 644 VAL A 675 GLY A 697 LEU A 818	P30 A1001 (-3.8A) P30 A1001 (-3.4A) P30 A1001 (-3.4A) None P30 A1001 (-3.4A) P30 A1001 (-4.6A)	0.72A	3aoxA-4rt7A: 24.6	3aoxA-4rt7A: 32.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tnb	G PROTEIN-COUPLED RECEPTOR KINASE 5 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ARG A 190 LEU A 192 ALA A 213 LEU A 263 MET A 266 GLY A 268 LEU A 318	None SGV A 601 (-4.1A) SGV A 601 (-3.3A) SGV A 601 (-4.5A) None None SGV A 601 (-4.9A)	1.18A	3aoxA-4tnbA: 20.6	3aoxA-4tnbA: 19.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tnb	G PROTEIN-COUPLED RECEPTOR KINASE 5 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ARG A 190 LEU A 192 ALA A 213 VAL A 247 LEU A 263 MET A 266 LEU A 318	None SGV A 601 (-4.1A) SGV A 601 (-3.3A) None SGV A 601 (-4.5A) None SGV A 601 (-4.9A)	0.86A	3aoxA-4tnbA: 20.6	3aoxA-4tnbA: 19.87
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tnb	G PROTEIN-COUPLED RECEPTOR KINASE 5 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 192 ALA A 213 LYS A 215 VAL A 247 LEU A 263 MET A 266 LEU A 318	SGV A 601 (-4.1A) SGV A 601 (-3.3A) SGV A 601 ( 4.2A) None SGV A 601 (-4.5A) None SGV A 601 (-4.9A)	0.78A	3aoxA-4tnbA: 20.6	3aoxA-4tnbA: 19.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	8	ARG A 12 LEU A 14 ALA A 35 LYS A 37 VAL A 65 MET A 84 GLY A 87 LEU A 136	None ACP A1264 ( 4.5A) ACP A1264 (-2.9A) None None None ACP A1264 (-3.5A) ACP A1264 ( 4.8A)	0.65A	3aoxA-4ueuA: 31.3	3aoxA-4ueuA: 39.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	8	ARG A 191 LEU A 193 ALA A 214 LYS A 216 VAL A 248 MET A 267 GLY A 270 LEU A 321	ANW A 601 ( 4.9A) ANW A 601 ( 4.0A) ANW A 601 (-3.4A) None None None ANW A 601 ( 4.5A) ANW A 601 (-4.9A)	0.78A	3aoxA-4wboA: 22.8	3aoxA-4wboA: 22.26
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	7	LEU B 267 ALA B 288 LYS B 290 VAL B 318 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.6A) 1N1 B 601 ( 4.3A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.59A	3aoxA-4xeyB: 25.2	3aoxA-4xeyB: 32.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 408 ALA A 428 VAL A 458 MET A 477 GLY A 480 LEU A 528	None	0.51A	3aoxA-4xi2A: 25.1	3aoxA-4xi2A: 28.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	7	LEU A 408 ALA A 428 LYS A 430 VAL A 458 MET A 477 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 (-2.4A) 746 A 702 (-3.7A) None None 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.49A	3aoxA-4y93A: 27.4	3aoxA-4y93A: 28.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ARG A 191 LEU A 193 ALA A 214 LYS A 216 VAL A 248 LEU A 264 LEU A 319	None AN2 A 601 ( 4.2A) AN2 A 601 (-3.6A) AN2 A 601 ( 3.9A) None AN2 A 601 ( 4.8A) None	1.07A	3aoxA-4yhjA: 20.8	3aoxA-4yhjA: 22.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ARG A 191 LEU A 193 LYS A 216 VAL A 248 LEU A 264 GLY A 270 LEU A 319	None AN2 A 601 ( 4.2A) AN2 A 601 ( 3.9A) None AN2 A 601 ( 4.8A) None None	1.22A	3aoxA-4yhjA: 20.8	3aoxA-4yhjA: 22.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 ALA A 214 LYS A 216 VAL A 248 LEU A 264 MET A 267 LEU A 319	AN2 A 601 ( 4.2A) AN2 A 601 (-3.6A) AN2 A 601 ( 3.9A) None AN2 A 601 ( 4.8A) None None	0.62A	3aoxA-4yhjA: 20.8	3aoxA-4yhjA: 22.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 193 LYS A 216 VAL A 248 LEU A 264 MET A 267 GLY A 270 LEU A 319	AN2 A 601 ( 4.2A) AN2 A 601 ( 3.9A) None AN2 A 601 ( 4.8A) None None None	0.84A	3aoxA-4yhjA: 20.8	3aoxA-4yhjA: 22.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ysj	CALMODULIN-LIKE DOMAIN PROTEIN KINASE (Eimeria tenella)	PF00069 (Pkinase) PF13499 (EF-hand_7)	6	ARG A 32 LEU A 34 ALA A 55 LYS A 57 GLY A 111 LEU A 158	None ADP A 506 ( 3.8A) ADP A 506 (-3.3A) ADP A 506 (-2.4A) None ADP A 506 (-4.7A)	0.94A	3aoxA-4ysjA: 23.4	3aoxA-4ysjA: 21.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	7	ARG A 97 LEU A 99 ALA A 120 LYS A 122 LEU A 170 GLY A 176 LEU A 223	None 5U5 A 401 (-3.8A) 5U5 A 401 (-3.5A) 5U5 A 401 (-2.6A) 5U5 A 401 (-3.8A) 5U5 A 401 (-3.4A) 5U5 A 401 (-4.7A)	0.75A	3aoxA-5eykA: 24.2	3aoxA-5eykA: 26.53
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5grn	PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 599 ALA A 625 LYS A 627 VAL A 658 GLY A 680 LEU A 825	748 A1001 (-3.8A) 748 A1001 (-3.7A) 748 A1001 (-4.0A) 748 A1001 ( 4.8A) 748 A1001 ( 4.0A) 748 A1001 (-4.3A)	0.93A	3aoxA-5grnA: 25.0	3aoxA-5grnA: 35.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	7	LEU A 20 ALA A 41 LYS A 43 VAL A 74 LEU A 92 GLY A 96 LEU A 143	ADP A 301 ( 4.0A) ADP A 301 (-3.5A) ADP A 301 (-2.7A) None ADP A 301 ( 4.8A) None ADP A 301 (-4.7A)	0.84A	3aoxA-5hu3A: 24.2	3aoxA-5hu3A: 26.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 718 ALA A 743 LYS A 745 LEU A 792 MET A 793 GLY A 796 LEU A 844	6HJ A1101 ( 4.6A) 6HJ A1101 (-3.1A) 6HJ A1101 (-4.2A) 6HJ A1101 ( 4.9A) None 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A)	0.39A	3aoxA-5j9zA: 31.6	3aoxA-5j9zA: 31.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jzn	SERINE/THREONINE-PRO TEIN KINASE DCLK1 (Homo sapiens)	PF00069 (Pkinase)	7	ARG A 394 ALA A 417 LYS A 419 VAL A 449 LEU A 467 GLY A 471 LEU A 518	None GUI A 701 ( 3.9A) GUI A 701 (-3.1A) None GUI A 701 ( 4.7A) GUI A 701 (-3.6A) GUI A 701 (-4.4A)	0.68A	3aoxA-5jznA: 22.5	3aoxA-5jznA: 26.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	ALA A 909 LYS A 911 VAL A 940 MET A 959 GLY A 962 LEU A1016	ATP A1200 (-3.5A) ATP A1200 (-3.8A) None None ATP A1200 ( 4.0A) ATP A1200 (-4.6A)	0.54A	3aoxA-5lpyA: 22.6	3aoxA-5lpyA: 27.07
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	ALA A 909 LYS A 911 VAL A 940 MET A 959 GLY A 962 LEU A1016	ADP A1200 (-3.5A) ADP A1200 ( 4.3A) None None ADP A1200 ( 4.0A) ADP A1200 (-4.7A)	0.54A	3aoxA-5lpzA: 22.6	3aoxA-5lpzA: 26.68
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 593 ALA A 617 LYS A 619 LEU A 671 MET A 674 GLY A 677	7AE A1000 ( 3.9A) 7AE A1000 (-3.3A) 7AE A1000 (-3.1A) 7AE A1000 (-3.7A) None 7AE A1000 ( 3.7A)	0.47A	3aoxA-5td2A: 11.8	3aoxA-5td2A: 35.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 542 ALA A 565 LYS A 567 LEU A 620 MET A 623 GLY A 626	7YS A9001 (-4.1A) 7YS A9001 (-3.3A) None 7YS A9001 (-4.2A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A)	0.68A	3aoxA-5u6bA: 29.5	3aoxA-5u6bA: 38.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 119 LYS A 121 VAL A 153 MET A 172 GLY A 175 LEU A 221	None	0.61A	3aoxA-5u7qA: 19.8	3aoxA-5u7qA: 25.12
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	8	ALA A 218 LYS A 220 VAL A 255 LEU A 271 LEU A 273 MET A 274 GLY A 277 LEU A 324	QRW A 601 (-3.4A) QRW A 601 (-3.0A) None QRW A 601 ( 4.9A) None MES A 604 (-3.9A) None None	0.70A	3aoxA-5uuuA: 21.8	3aoxA-5uuuA: 21.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5uuu	BETA-ADRENERGIC RECEPTOR KINASE 1 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	ALA A 218 VAL A 255 LEU A 271 LEU A 273 MET A 274 GLY A 276 LEU A 324	QRW A 601 (-3.4A) None QRW A 601 ( 4.9A) None MES A 604 (-3.9A) None None	0.97A	3aoxA-5uuuA: 21.8	3aoxA-5uuuA: 21.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	6	LEU A 24 ALA A 45 LYS A 47 MET A 98 GLY A 101 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 (-3.3A) 9WS A 401 (-3.3A) None 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A)	0.69A	3aoxA-5w5jA: 10.0	3aoxA-5w5jA: 27.08
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	6	LEU A 33 ALA A 54 LYS A 56 VAL A 83 GLY A 105 LEU A 153	ANP A 501 ( 3.8A) ANP A 501 ( 3.7A) ANP A 501 (-2.4A) None ANP A 501 ( 4.0A) ANP A 501 (-4.6A)	0.83A	3aoxA-6ao5A: 7.7	3aoxA-6ao5A: 24.04
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	6	ALA A 192 LYS A 194 VAL A 249 LEU A 269 GLY A 273 LEU A 319	BI9 A 501 (-3.3A) NH4 A 506 ( 4.4A) None BI9 A 501 (-4.4A) BI9 A 501 (-3.3A) BI9 A 501 (-4.7A)	0.48A	3aoxA-6bqlA: 22.3	3aoxA-6bqlA: 13.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	ARG A 879 LEU A 881 ALA A 906 LYS A 908 VAL A 938 GLY A 962 LEU A1010	None ADP A1201 ( 4.5A) ADP A1201 (-3.4A) ADP A1201 (-2.8A) None ADP A1201 ( 4.1A) ADP A1201 (-4.5A)	0.76A	3aoxA-6c7yA: 27.8	3aoxA-6c7yA: 15.03
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	6	ALA A 155 LYS A 157 VAL A 212 LEU A 232 GLY A 236 LEU A 282	H1N A 501 (-3.4A) H1N A 501 (-2.8A) H1N A 501 (-4.9A) H1N A 501 (-4.3A) H1N A 501 (-3.6A) H1N A 501 (-4.8A)	0.55A	3aoxA-6ccfA: 22.0	3aoxA-6ccfA: 13.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	7	ARG A 195 LEU A 197 ALA A 217 LEU A 266 MET A 267 GLY A 270 LEU A 319	None FKY A9001 (-4.1A) FKY A9001 (-3.3A) FKY A9001 (-4.4A) None FKY A9001 (-3.3A) FKY A9001 ( 4.9A)	0.83A	3aoxA-6cz4A: 29.0	3aoxA-6cz4A: 16.96

[["3AOX_A_EMHA901_1","1k2p","Homo sapiens","TYROSINE-PROTEIN KINASE BTK","PF07714(Pkinase_Tyr)",6,"ALA A 428;LYS A 430;VAL A 458;MET A 477;GLY A 480;LEU A 528","None","0.53A","3aoxA-1k2pA:28.3","3aoxA-1k2pA:33.72"],["3AOX_A_EMHA901_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"ALA A 220;LYS A 222;VAL A 249;MET A 269;GLY A 272;LEU A 321","None","0.50A","3aoxA-1k9aA:27.1","3aoxA-1k9aA:27.22"],["3AOX_A_EMHA901_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 267;ALA A 288;VAL A 318;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-3.4A);P16 A   2 ( 4.7A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.74A","3aoxA-1opkA:30.4","3aoxA-1opkA:27.15"],["3AOX_A_EMHA901_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",7,"LEU A  78;ALA A  99;LYS A 101;VAL A 131;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-3.6A);ATP A 535 ( 2.5A);5EA A1001 (-4.5A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.83A","3aoxA-1s9iA:21.7","3aoxA-1s9iA:25.06"],["3AOX_A_EMHA901_1","1snx","Homo sapiens","TYROSINE-PROTEIN KINASE ITK\/TSK","PF07714(Pkinase_Tyr)",6,"ALA A 389;LYS A 391;VAL A 419;MET A 438;GLY A 441;LEU A 489","None","0.58A","3aoxA-1snxA:22.6","3aoxA-1snxA:35.19"],["3AOX_A_EMHA901_1","1zlt","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK1","PF00069(Pkinase)",7,"LEU A  15;ALA A  36;LYS A  38;VAL A  68;LEU A  84;GLY A  90;LEU A 137","HYM A 400 (-4.2A);HYM A 400 (-3.5A);HYM A 400 (-3.2A);HYM A 400 (-4.8A);HYM A 400 (-4.2A);None;HYM A 400 (-4.5A)","0.66A","3aoxA-1zltA:20.9","3aoxA-1zltA:24.15"],["3AOX_A_EMHA901_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",6,"LEU X  17;ALA X  37;VAL X  67;MET X  85;GLY X  88;LEU X 137","STU X 902 (-3.8A);STU X 902 (-3.1A);None;None;STU X 902 (-3.5A);STU X 902 (-4.4A)","0.66A","3aoxA-2dq7X:30.4","3aoxA-2dq7X:35.03"],["3AOX_A_EMHA901_1","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",6,"LEU A  19;ALA A  40;LYS A  42;LEU A  95;MET A  96;LEU A 144","ADP A 500 (-4.3A);ADP A 500 ( 3.7A);ADP A 500 (-2.9A);ADP A 500 ( 4.9A);None;ADP A 500 (-4.3A)","0.60A","3aoxA-2f9gA:21.9","3aoxA-2f9gA:24.02"],["3AOX_A_EMHA901_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;ALA A 293;LYS A 295;VAL A 323;MET A 341;GLY A 344;LEU A 393","H8H A 534 (-3.8A);H8H A 534 (-3.2A);H8H A 534 (-3.7A);None;None;H8H A 534 (-3.3A);H8H A 534 (-4.5A)","0.72A","3aoxA-2h8hA:29.1","3aoxA-2h8hA:25.09"],["3AOX_A_EMHA901_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 273;ALA A 293;VAL A 323;MET A 341;GLY A 344;LEU A 393","QUE A   1 (-3.9A);QUE A   1 (-3.5A);None;None;QUE A   1 (-3.0A);QUE A   1 (-4.4A)","0.62A","3aoxA-2hckA:28.2","3aoxA-2hckA:29.49"],["3AOX_A_EMHA901_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;ALA A 271;LYS A 273;VAL A 301;MET A 319;GLY A 322;LEU A 371","1BM A 499 ( 3.7A);1BM A 499 (-3.6A);1BM A 499 (-3.8A);None;None;1BM A 499 (-3.5A);1BM A 499 (-4.4A)","0.59A","3aoxA-2hk5A:30.8","3aoxA-2hk5A:33.92"],["3AOX_A_EMHA901_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",7,"LEU A 248;ALA A 269;LYS A 271;VAL A 299;MET A 318;GLY A 321;LEU A 370","GIN A 600 ( 4.6A);GIN A 600 (-3.1A);GIN A 600 (-3.6A);GIN A 600 (-4.6A);None;None;GIN A 600 (-4.7A)","0.77A","3aoxA-2hz0A:30.0","3aoxA-2hz0A:35.47"],["3AOX_A_EMHA901_1","2j0j","Gallus gallus","FOCAL ADHESION KINASE 1","PF00373(FERM_M);PF07714(Pkinase_Tyr)",6,"ARG A 426;ALA A 452;VAL A 484;LEU A 501;GLY A 505;LEU A 553","None;4ST A1687 (-3.3A);None;4ST A1687 (-4.3A);4ST A1687 (-3.2A);4ST A1687 (-4.4A)","0.84A","3aoxA-2j0jA:32.0","3aoxA-2j0jA:20.35"],["3AOX_A_EMHA901_1","2jkm","Gallus gallus","FOCAL ADHESION KINASE 1","PF07714(Pkinase_Tyr)",6,"ALA A 452;LYS A 454;VAL A 484;LEU A 501;GLY A 505;LEU A 553","BII A1687 (-3.5A);BII A1687 (-2.9A);None;BII A1687 (-4.4A);BII A1687 (-3.6A);BII A1687 (-4.2A)","0.68A","3aoxA-2jkmA:31.1","3aoxA-2jkmA:35.89"],["3AOX_A_EMHA901_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;ALA A 271;LYS A 273;VAL A 301;MET A 319;GLY A 322;LEU A 371","None;1N8 A 501 ( 3.4A);1N8 A 501 ( 3.4A);None;1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A)","0.93A","3aoxA-2og8A:29.4","3aoxA-2og8A:40.14"],["3AOX_A_EMHA901_1","2ogv","Homo sapiens","MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR PRECURSOR","PF07714(Pkinase_Tyr)",6,"LEU A 588;ALA A 614;LYS A 616;VAL A 647;GLY A 669;LEU A 785","None","0.69A","3aoxA-2ogvA:20.4","3aoxA-2ogvA:36.18"],["3AOX_A_EMHA901_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 344;ALA A 367;LYS A 369;VAL A 399;GLY A 419;LEU A 468","ANP A 615 (-4.4A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;None;ANP A 615 (-4.7A)","0.88A","3aoxA-2ozoA:24.8","3aoxA-2ozoA:24.34"],["3AOX_A_EMHA901_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 344;ALA A 367;LYS A 369;VAL A 399;GLY A 420;LEU A 468","ANP A 615 (-4.4A);ANP A 615 (-3.3A);ANP A 615 (-3.1A);None;ANP A 615 ( 3.9A);ANP A 615 (-4.7A)","0.65A","3aoxA-2ozoA:24.8","3aoxA-2ozoA:24.34"],["3AOX_A_EMHA901_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",6,"LEU A  25;ALA A  46;LEU A 105;MET A 106;GLY A 109;LEU A 156","ATP A 381 ( 4.3A);ATP A 381 (-3.5A);None;None;None;ATP A 381 ( 4.8A)","0.44A","3aoxA-2phkA:22.2","3aoxA-2phkA:23.55"],["3AOX_A_EMHA901_1","2pmo","Plasmodium falciparum","SER\/THR PROTEIN KINASE","PF00069(Pkinase)",6,"ARG X  32;LEU X  34;ALA X  53;LYS X  55;MET X 120;LEU X 179","None;HMD X 400 ( 4.3A);HMD X 400 (-3.5A);HMD X 400 (-4.2A);None;HMD X 400 (-4.7A)","0.86A","3aoxA-2pmoX:21.4","3aoxA-2pmoX:24.23"],["3AOX_A_EMHA901_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"ALA B  67;LYS B  69;VAL B  98;MET B 117;GLY B 120;LEU B 171","None","0.55A","3aoxA-2qkwB:17.6","3aoxA-2qkwB:28.07"],["3AOX_A_EMHA901_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",8,"LEU A 724;ALA A 749;LYS A 751;VAL A 781;LEU A 798;MET A 799;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 (-3.3A);GW7 A   1 (-3.9A);GW7 A   1 ( 4.7A);GW7 A   1 (-4.5A);None;GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.98A","3aoxA-2r4bA:23.4","3aoxA-2r4bA:32.08"],["3AOX_A_EMHA901_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",7,"LEU A 226;ALA A 247;LEU A 301;LEU A 303;MET A 304;GLY A 307;LEU A 354","XK9 A1511 (-3.8A);XK9 A1511 ( 4.1A);XK9 A1511 (-4.6A);XK9 A1511 (-4.1A);None;XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A)","0.60A","3aoxA-2xk9A:12.8","3aoxA-2xk9A:25.75"],["3AOX_A_EMHA901_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",6,"LEU A  68;ALA A  92;LYS A  94;VAL A 125;LEU A 141;GLY A 147","STU A   1 (-3.8A);STU A   1 (-3.3A);STU A   1 (-2.8A);None;STU A   1 ( 4.6A);STU A   1 ( 3.9A)","0.85A","3aoxA-2z7rA:21.3","3aoxA-2z7rA:24.66"],["3AOX_A_EMHA901_1","2z7r","Homo sapiens","RIBOSOMAL PROTEIN S6 KINASE ALPHA-1","PF00069(Pkinase)",6,"LEU A  68;ALA A  92;VAL A 125;LEU A 141;GLY A 147;LEU A 194","STU A   1 (-3.8A);STU A   1 (-3.3A);None;STU A   1 ( 4.6A);STU A   1 ( 3.9A);STU A   1 (-4.6A)","0.87A","3aoxA-2z7rA:21.3","3aoxA-2z7rA:24.66"],["3AOX_A_EMHA901_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",8,"ARG A1000;LEU A1002;ALA A1028;LYS A1030;VAL A1060;LEU A1078;MET A1079;GLY A1082","None;S91 A   1 ( 4.1A);S91 A   1 (-3.2A);S91 A   1 ( 4.2A);None;S91 A   1 (-4.7A);None;S91 A   1 (-3.3A)","0.66A","3aoxA-2z8cA:29.6","3aoxA-2z8cA:44.41"],["3AOX_A_EMHA901_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",7,"LEU A 253;ALA A 273;LYS A 275;VAL A 303;MET A 322;GLY A 325;LEU A 374","None","0.38A","3aoxA-2zv7A:31.4","3aoxA-2zv7A:34.29"],["3AOX_A_EMHA901_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"ALA A 220;LYS A 222;VAL A 249;MET A 269;GLY A 272;LEU A 321","None","0.50A","3aoxA-3d7uA:27.1","3aoxA-3d7uA:33.04"],["3AOX_A_EMHA901_1","3fme","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"LEU A  59;ALA A  80;VAL A 113;LEU A 131;MET A 132;LEU A 186","STU A   1 (-3.8A);STU A   1 (-3.4A);None;STU A   1 (-4.6A);None;STU A   1 (-4.4A)","0.72A","3aoxA-3fmeA:21.0","3aoxA-3fmeA:26.37"],["3AOX_A_EMHA901_1","3fzp","Homo sapiens","PROTEIN TYROSINE KINASE 2 BETA","PF07714(Pkinase_Tyr)",7,"LEU A 431;ALA A 455;LYS A 457;VAL A 487;LEU A 504;GLY A 508;LEU A 556","AGS A 999 ( 4.4A);AGS A 999 (-3.6A);AGS A 999 (-2.5A);None;AGS A 999 (-4.4A);None;AGS A 999 (-4.5A)","0.99A","3aoxA-3fzpA:30.9","3aoxA-3fzpA:35.14"],["3AOX_A_EMHA901_1","3i6u","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE CHK2","PF00069(Pkinase);PF00498(FHA)",7,"LEU A 226;ALA A 247;LEU A 301;LEU A 303;MET A 304;GLY A 307;LEU A 354","None","0.85A","3aoxA-3i6uA:21.3","3aoxA-3i6uA:23.91"],["3AOX_A_EMHA901_1","3lj0","Saccharomyces cerevisiae","SERINE\/THREONINE-PROTEIN KINASE\/ENDORIBONUCLEASE IRE1","PF00069(Pkinase);PF06479(Ribonuc_2-5A)",6,"LEU A 680;ALA A 700;LYS A 702;LEU A 745;LEU A 747;LEU A 804","ADP A2101 ( 4.1A);ADP A2101 (-3.5A);ADP A2101 (-2.7A);ADP A2101 ( 4.4A);None;ADP A2101 (-4.4A)","0.63A","3aoxA-3lj0A:22.6","3aoxA-3lj0A:22.68"],["3AOX_A_EMHA901_1","3lw0","Homo sapiens","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","PF07714(Pkinase_Tyr)",7,"ARG A1003;LEU A1005;ALA A1031;VAL A1063;LEU A1081;MET A1082;GLY A1085","None;None;None;CCX A   1 (-4.1A);None;None;None","0.54A","3aoxA-3lw0A:29.4","3aoxA-3lw0A:39.39"],["3AOX_A_EMHA901_1","3nuu","Homo sapiens","PKB-LIKE","PF00069(Pkinase)",6,"LEU A  88;ALA A 109;LYS A 111;LEU A 159;GLY A 165;LEU A 212","JOZ A 361 (-4.1A);JOZ A 361 (-3.4A);SO4 A   5 (-2.8A);JOZ A 361 (-4.0A);None;None","0.81A","3aoxA-3nuuA:23.2","3aoxA-3nuuA:23.36"],["3AOX_A_EMHA901_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",7,"ALA A 213;VAL A 247;LEU A 263;LEU A 265;MET A 266;GLY A 268;LEU A 318","AMP A 577 (-3.4A);None;AMP A 577 ( 4.7A);AMP A 577 ( 4.9A);None;None;AMP A 577 (-4.8A)","1.11A","3aoxA-3nyoA:22.1","3aoxA-3nyoA:21.64"],["3AOX_A_EMHA901_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",7,"ARG A 190;LEU A 192;ALA A 213;LYS A 215;LEU A 263;GLY A 269;LEU A 318","None;AMP A 577 ( 4.3A);AMP A 577 (-3.4A);AMP A 577 (-2.8A);AMP A 577 ( 4.7A);None;AMP A 577 (-4.8A)","1.18A","3aoxA-3nyoA:22.1","3aoxA-3nyoA:21.64"],["3AOX_A_EMHA901_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",9,"LEU A 192;ALA A 213;LYS A 215;VAL A 247;LEU A 263;LEU A 265;MET A 266;GLY A 269;LEU A 318","AMP A 577 ( 4.3A);AMP A 577 (-3.4A);AMP A 577 (-2.8A);None;AMP A 577 ( 4.7A);AMP A 577 ( 4.9A);None;None;AMP A 577 (-4.8A)","0.60A","3aoxA-3nyoA:22.1","3aoxA-3nyoA:21.64"],["3AOX_A_EMHA901_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"LEU A 726;ALA A 751;LEU A 800;MET A 801;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-3.1A);03Q A   1 (-4.6A);None;03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.65A","3aoxA-3pp0A:30.5","3aoxA-3pp0A:33.33"],["3AOX_A_EMHA901_1","3sxs","Homo sapiens","CYTOPLASMIC TYROSINE-PROTEIN KINASE BMX","PF07714(Pkinase_Tyr)",6,"LEU A 423;ALA A 443;LYS A 445;VAL A 473;GLY A 495;LEU A 543","PP2 A   1 (-4.1A);PP2 A   1 (-3.2A);PP2 A   1 (-4.5A);None;PP2 A   1 ( 4.2A);PP2 A   1 (-4.6A)","0.72A","3aoxA-3sxsA:24.9","3aoxA-3sxsA:33.62"],["3AOX_A_EMHA901_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"ARG A 542;LEU A 544;ALA A 570;VAL A 601;MET A 620;GLY A 623;LEU A 686","None;0F4 A 902 ( 4.2A);0F4 A 902 (-3.2A);None;None;0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.64A","3aoxA-3v5qA:30.6","3aoxA-3v5qA:37.68"],["3AOX_A_EMHA901_1","3vn9","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"LEU A  59;ALA A  80;VAL A 113;LEU A 131;MET A 132;LEU A 186","None;ANK A 401 (-3.0A);None;None;None;ANK A 401 ( 4.9A)","0.64A","3aoxA-3vn9A:21.5","3aoxA-3vn9A:26.24"],["3AOX_A_EMHA901_1","3w18","Homo sapiens","AURORA KINASE A","PF00069(Pkinase)",7,"ARG A 137;LEU A 139;ALA A 160;LYS A 162;LEU A 210;GLY A 216;LEU A 263","N13 A 501 ( 4.6A);N13 A 501 (-3.7A);N13 A 501 ( 4.1A);N13 A 501 (-2.9A);N13 A 501 ( 4.8A);N13 A 501 (-3.5A);N13 A 501 (-4.5A)","1.17A","3aoxA-3w18A:21.6","3aoxA-3w18A:24.72"],["3AOX_A_EMHA901_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"LEU A  75;ALA A  96;LYS A  98;VAL A 128;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 (-3.2A);ANP A 401 (-2.7A);CHU A 403 (-4.2A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.65A","3aoxA-3wigA:22.8","3aoxA-3wigA:24.33"],["3AOX_A_EMHA901_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",6,"ALA A1978;LEU A2026;LEU A2028;MET A2029;GLY A2031;LEU A2086","VGH A3000 (-3.4A);VGH A3000 ( 4.2A);VGH A3000 ( 4.8A);None;None;VGH A3000 (-4.3A)","0.90A","3aoxA-3zbfA:33.8","3aoxA-3zbfA:45.64"],["3AOX_A_EMHA901_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",7,"LEU A1951;ALA A1978;LEU A2026;LEU A2028;MET A2029;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.2A);VGH A3000 ( 4.8A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.44A","3aoxA-3zbfA:33.8","3aoxA-3zbfA:45.64"],["3AOX_A_EMHA901_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",7,"LEU A1951;ALA A1978;LYS A1980;LEU A2026;LEU A2028;GLY A2032;LEU A2086","VGH A3000 ( 4.4A);VGH A3000 (-3.4A);VGH A3000 ( 4.7A);VGH A3000 ( 4.2A);VGH A3000 ( 4.8A);VGH A3000 (-3.5A);VGH A3000 (-4.3A)","0.54A","3aoxA-3zbfA:33.8","3aoxA-3zbfA:45.64"],["3AOX_A_EMHA901_1","4a4l","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK1","PF00069(Pkinase)",7,"ARG A  57;LEU A  59;ALA A  80;LYS A  82;VAL A 114;LEU A 130;LEU A 132","939 A1331 (-3.9A);939 A1331 (-3.7A);939 A1331 (-3.5A);939 A1331 (-2.6A);None;939 A1331 ( 4.7A);939 A1331 (-4.4A)","0.76A","3aoxA-4a4lA:23.5","3aoxA-4a4lA:25.75"],["3AOX_A_EMHA901_1","4agd","Homo sapiens","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 840;ALA A 866;LYS A 868;VAL A 899;GLY A 922;LEU A1035","B49 A2000 (-3.7A);B49 A2000 (-3.5A);B49 A2000 (-3.0A);B49 A2000 ( 4.6A);B49 A2000 ( 3.7A);B49 A2000 (-4.5A)","0.78A","3aoxA-4agdA:29.6","3aoxA-4agdA:33.79"],["3AOX_A_EMHA901_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",7,"ARG A 558;LEU A 560;ALA A 586;VAL A 617;MET A 636;GLY A 639;LEU A 699","None;LTI A1839 ( 4.2A);LTI A1839 (-3.3A);None;None;LTI A1839 (-3.4A);LTI A1839 (-4.2A)","0.64A","3aoxA-4at3A:30.7","3aoxA-4at3A:36.29"],["3AOX_A_EMHA901_1","4b6l","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK3","PF00069(Pkinase)",7,"ARG A  66;LEU A  68;ALA A  89;LYS A  91;VAL A 123;LEU A 139;LEU A 141","9ZP A1333 (-3.3A);9ZP A1333 (-3.9A);9ZP A1333 (-3.5A);None;9ZP A1333 (-4.4A);9ZP A1333 (-3.8A);9ZP A1333 (-4.7A)","0.72A","3aoxA-4b6lA:23.5","3aoxA-4b6lA:24.21"],["3AOX_A_EMHA901_1","4e93","Homo sapiens","TYROSINE-PROTEIN KINASE FES\/FPS","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"ALA A 588;LYS A 590;VAL A 620;LEU A 638;GLY A 642;LEU A 690","GUI A 901 (-3.4A);GUI A 901 (-2.8A);None;GUI A 901 (-4.4A);GUI A 901 (-3.5A);GUI A 901 (-4.3A)","0.53A","3aoxA-4e93A:32.9","3aoxA-4e93A:34.79"],["3AOX_A_EMHA901_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 515;ALA A 541;VAL A 572;MET A 591;GLY A 594;LEU A 656","None","0.49A","3aoxA-4f0iA:25.2","3aoxA-4f0iA:37.32"],["3AOX_A_EMHA901_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",6,"LEU A 377;ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501","0SB A 701 ( 3.9A);0SB A 701 (-3.3A);0SB A 701 ( 4.8A);None;0SB A 701 (-3.5A);0SB A 701 (-4.4A)","0.43A","3aoxA-4f4pA:24.8","3aoxA-4f4pA:32.46"],["3AOX_A_EMHA901_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 377;ALA A 400;LYS A 402;VAL A 433;GLY A 454;LEU A 501","ANP A 701 ( 4.6A);ANP A 701 (-3.3A);ANP A 701 (-2.7A);ANP A 701 (-4.8A);ANP A 701 ( 4.2A);ANP A 701 (-4.5A)","0.60A","3aoxA-4fl3A:20.4","3aoxA-4fl3A:21.99"],["3AOX_A_EMHA901_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",7,"ALA A1148;VAL A1180;LEU A1196;LEU A1198;MET A1199;GLY A1201;LEU A1256","0UV A1501 (-3.4A);0UV A1501 ( 4.9A);0UV A1501 (-3.7A);0UV A1501 ( 4.8A);None;0UV A1501 (-4.4A);0UV A1501 (-4.6A)","0.97A","3aoxA-4fodA:48.3","3aoxA-4fodA:99.70"],["3AOX_A_EMHA901_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",9,"LEU A1122;ALA A1148;LYS A1150;VAL A1180;LEU A1196;LEU A1198;MET A1199;GLY A1202;LEU A1256","0UV A1501 (-3.8A);0UV A1501 (-3.4A);0UV A1501 (-3.7A);0UV A1501 ( 4.9A);0UV A1501 (-3.7A);0UV A1501 ( 4.8A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A)","0.42A","3aoxA-4fodA:48.3","3aoxA-4fodA:99.70"],["3AOX_A_EMHA901_1","4hzs","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr);PF14604(SH3_9)",6,"LEU A 132;ALA A 156;LYS A 158;LEU A 207;GLY A 211;LEU A 259","None","0.66A","3aoxA-4hzsA:19.4","3aoxA-4hzsA:32.66"],["3AOX_A_EMHA901_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"LEU A 132;ALA A 156;LYS A 158;LEU A 207;GLY A 211;LEU A 259","1G0 A 401 ( 4.5A);1G0 A 401 (-3.6A);1G0 A 401 (-3.7A);1G0 A 401 ( 4.9A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A)","0.56A","3aoxA-4id7A:30.2","3aoxA-4id7A:33.33"],["3AOX_A_EMHA901_1","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",6,"LEU A 406;ALA A 427;LYS A 429;VAL A 453;LEU A 471;LEU A 522","T28 A 701 (-3.8A);T28 A 701 (-3.0A);T28 A 701 ( 3.8A);None;T28 A 701 ( 4.8A);T28 A 701 (-3.9A)","0.84A","3aoxA-4idtA:22.7","3aoxA-4idtA:24.09"],["3AOX_A_EMHA901_1","4idt","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 14","PF00069(Pkinase)",6,"LEU A 406;ALA A 427;VAL A 453;LEU A 471;GLY A 475;LEU A 522","T28 A 701 (-3.8A);T28 A 701 (-3.0A);None;T28 A 701 ( 4.8A);T28 A 701 ( 3.0A);T28 A 701 (-3.9A)","0.87A","3aoxA-4idtA:22.7","3aoxA-4idtA:24.09"],["3AOX_A_EMHA901_1","4j7b","Danio rerio","POLO-LIKE KINASE","PF00069(Pkinase)",6,"ARG A  43;LEU A  45;ALA A  66;LYS A  68;VAL A 100;LEU A 116","None","0.68A","3aoxA-4j7bA:23.3","3aoxA-4j7bA:24.59"],["3AOX_A_EMHA901_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;ALA A 293;LYS A 295;VAL A 323;MET A 341;GLY A 344;LEU A 393","0J9 A 601 (-4.0A);0J9 A 601 (-3.3A);0J9 A 601 ( 4.7A);None;None;0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A)","0.63A","3aoxA-4k11A:29.0","3aoxA-4k11A:28.99"],["3AOX_A_EMHA901_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",6,"LEU A  33;ALA A  54;LYS A  56;VAL A  83;GLY A 105;LEU A 153","GOL A 404 ( 3.6A);GOL A 404 ( 3.1A);GOL A 403 ( 4.6A);GOL A 403 (-4.1A);GOL A 404 (-3.6A);GOL A 403 ( 4.4A)","0.54A","3aoxA-4lg4A:18.0","3aoxA-4lg4A:25.53"],["3AOX_A_EMHA901_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",7,"LEU A 273;ALA A 293;LYS A 295;VAL A 323;MET A 341;GLY A 344;LEU A 393","VGG A 601 (-3.2A);VGG A 601 (-3.5A);VGG A 601 (-3.8A);VGG A 601 ( 4.8A);None;VGG A 601 ( 3.2A);VGG A 601 (-4.5A)","0.42A","3aoxA-4lggA:28.9","3aoxA-4lggA:33.33"],["3AOX_A_EMHA901_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",8,"ALA A 218;LYS A 220;VAL A 255;LEU A 271;LEU A 273;MET A 274;GLY A 276;LEU A 324","29X A 702 (-3.1A);29X A 702 (-3.6A);29X A 702 (-4.8A);29X A 702 ( 4.7A);29X A 702 (-4.6A);None;None;29X A 702 (-4.6A)","0.88A","3aoxA-4mk0A:21.5","3aoxA-4mk0A:19.45"],["3AOX_A_EMHA901_1","4mk0","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00169(PH);PF00615(RGS)",8,"ALA A 218;LYS A 220;VAL A 255;LEU A 271;LEU A 273;MET A 274;GLY A 277;LEU A 324","29X A 702 (-3.1A);29X A 702 (-3.6A);29X A 702 (-4.8A);29X A 702 ( 4.7A);29X A 702 (-4.6A);None;None;29X A 702 (-4.6A)","0.76A","3aoxA-4mk0A:21.5","3aoxA-4mk0A:19.45"],["3AOX_A_EMHA901_1","4o1o","Sus scrofa","RIBONUCLEASE L","PF00069(Pkinase);PF06479(Ribonuc_2-5A);PF12796(Ank_2);PF13857(Ank_5)",6,"ALA A 388;LYS A 390;VAL A 416;LEU A 432;LEU A 434;LEU A 489","None","0.59A","3aoxA-4o1oA:16.3","3aoxA-4o1oA:17.91"],["3AOX_A_EMHA901_1","4o38","Homo sapiens","CYCLIN-G-ASSOCIATED KINASE","PF00069(Pkinase)",8,"ARG A  44;LEU A  46;ALA A  67;LYS A  69;VAL A  99;LEU A 125;GLY A 128;LEU A 180","None;SIN A 401 ( 3.9A);SIN A 401 ( 3.7A);None;None;SIN A 401 ( 4.8A);SIN A 401 (-3.5A);SIN A 401 ( 4.5A)","0.73A","3aoxA-4o38A:20.2","3aoxA-4o38A:24.73"],["3AOX_A_EMHA901_1","4rt7","Homo sapiens","RECEPTOR-TYPE TYROSINE-PROTEIN KINASE FLT3","PF07714(Pkinase_Tyr)",6,"LEU A 616;ALA A 642;LYS A 644;VAL A 675;GLY A 697;LEU A 818","P30 A1001 (-3.8A);P30 A1001 (-3.4A);P30 A1001 (-3.4A);None;P30 A1001 (-3.4A);P30 A1001 (-4.6A)","0.72A","3aoxA-4rt7A:24.6","3aoxA-4rt7A:32.46"],["3AOX_A_EMHA901_1","4tnb","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 5","PF00069(Pkinase);PF00615(RGS)",7,"ARG A 190;LEU A 192;ALA A 213;LEU A 263;MET A 266;GLY A 268;LEU A 318","None;SGV A 601 (-4.1A);SGV A 601 (-3.3A);SGV A 601 (-4.5A);None;None;SGV A 601 (-4.9A)","1.18A","3aoxA-4tnbA:20.6","3aoxA-4tnbA:19.87"],["3AOX_A_EMHA901_1","4tnb","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 5","PF00069(Pkinase);PF00615(RGS)",7,"ARG A 190;LEU A 192;ALA A 213;VAL A 247;LEU A 263;MET A 266;LEU A 318","None;SGV A 601 (-4.1A);SGV A 601 (-3.3A);None;SGV A 601 (-4.5A);None;SGV A 601 (-4.9A)","0.86A","3aoxA-4tnbA:20.6","3aoxA-4tnbA:19.87"],["3AOX_A_EMHA901_1","4tnb","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 5","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 192;ALA A 213;LYS A 215;VAL A 247;LEU A 263;MET A 266;LEU A 318","SGV A 601 (-4.1A);SGV A 601 (-3.3A);SGV A 601 ( 4.2A);None;SGV A 601 (-4.5A);None;SGV A 601 (-4.9A)","0.78A","3aoxA-4tnbA:20.6","3aoxA-4tnbA:19.87"],["3AOX_A_EMHA901_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",8,"ARG A  12;LEU A  14;ALA A  35;LYS A  37;VAL A  65;MET A  84;GLY A  87;LEU A 136","None;ACP A1264 ( 4.5A);ACP A1264 (-2.9A);None;None;None;ACP A1264 (-3.5A);ACP A1264 ( 4.8A)","0.65A","3aoxA-4ueuA:31.3","3aoxA-4ueuA:39.23"],["3AOX_A_EMHA901_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",8,"ARG A 191;LEU A 193;ALA A 214;LYS A 216;VAL A 248;MET A 267;GLY A 270;LEU A 321","ANW A 601 ( 4.9A);ANW A 601 ( 4.0A);ANW A 601 (-3.4A);None;None;None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A)","0.78A","3aoxA-4wboA:22.8","3aoxA-4wboA:22.26"],["3AOX_A_EMHA901_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",7,"LEU B 267;ALA B 288;LYS B 290;VAL B 318;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 (-3.5A);1N1 B 601 (-4.6A);1N1 B 601 ( 4.3A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.59A","3aoxA-4xeyB:25.2","3aoxA-4xeyB:32.62"],["3AOX_A_EMHA901_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 408;ALA A 428;VAL A 458;MET A 477;GLY A 480;LEU A 528","None","0.51A","3aoxA-4xi2A:25.1","3aoxA-4xi2A:28.13"],["3AOX_A_EMHA901_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",7,"LEU A 408;ALA A 428;LYS A 430;VAL A 458;MET A 477;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 (-2.4A);746 A 702 (-3.7A);None;None;746 A 702 (-3.6A);746 A 702 (-4.4A)","0.49A","3aoxA-4y93A:27.4","3aoxA-4y93A:28.34"],["3AOX_A_EMHA901_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",7,"ARG A 191;LEU A 193;ALA A 214;LYS A 216;VAL A 248;LEU A 264;LEU A 319","None;AN2 A 601 ( 4.2A);AN2 A 601 (-3.6A);AN2 A 601 ( 3.9A);None;AN2 A 601 ( 4.8A);None","1.07A","3aoxA-4yhjA:20.8","3aoxA-4yhjA:22.03"],["3AOX_A_EMHA901_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",7,"ARG A 191;LEU A 193;LYS A 216;VAL A 248;LEU A 264;GLY A 270;LEU A 319","None;AN2 A 601 ( 4.2A);AN2 A 601 ( 3.9A);None;AN2 A 601 ( 4.8A);None;None","1.22A","3aoxA-4yhjA:20.8","3aoxA-4yhjA:22.03"],["3AOX_A_EMHA901_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;ALA A 214;LYS A 216;VAL A 248;LEU A 264;MET A 267;LEU A 319","AN2 A 601 ( 4.2A);AN2 A 601 (-3.6A);AN2 A 601 ( 3.9A);None;AN2 A 601 ( 4.8A);None;None","0.62A","3aoxA-4yhjA:20.8","3aoxA-4yhjA:22.03"],["3AOX_A_EMHA901_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 193;LYS A 216;VAL A 248;LEU A 264;MET A 267;GLY A 270;LEU A 319","AN2 A 601 ( 4.2A);AN2 A 601 ( 3.9A);None;AN2 A 601 ( 4.8A);None;None;None","0.84A","3aoxA-4yhjA:20.8","3aoxA-4yhjA:22.03"],["3AOX_A_EMHA901_1","4ysj","Eimeria tenella","CALMODULIN-LIKE DOMAIN PROTEIN KINASE","PF00069(Pkinase);PF13499(EF-hand_7)",6,"ARG A  32;LEU A  34;ALA A  55;LYS A  57;GLY A 111;LEU A 158","None;ADP A 506 ( 3.8A);ADP A 506 (-3.3A);ADP A 506 (-2.4A);None;ADP A 506 (-4.7A)","0.94A","3aoxA-4ysjA:23.4","3aoxA-4ysjA:21.54"],["3AOX_A_EMHA901_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",7,"ARG A  97;LEU A  99;ALA A 120;LYS A 122;LEU A 170;GLY A 176;LEU A 223","None;5U5 A 401 (-3.8A);5U5 A 401 (-3.5A);5U5 A 401 (-2.6A);5U5 A 401 (-3.8A);5U5 A 401 (-3.4A);5U5 A 401 (-4.7A)","0.75A","3aoxA-5eykA:24.2","3aoxA-5eykA:26.53"],["3AOX_A_EMHA901_1","5grn","Homo sapiens","PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA","PF07714(Pkinase_Tyr)",6,"LEU A 599;ALA A 625;LYS A 627;VAL A 658;GLY A 680;LEU A 825","748 A1001 (-3.8A);748 A1001 (-3.7A);748 A1001 (-4.0A);748 A1001 ( 4.8A);748 A1001 ( 4.0A);748 A1001 (-4.3A)","0.93A","3aoxA-5grnA:25.0","3aoxA-5grnA:35.85"],["3AOX_A_EMHA901_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",7,"LEU A  20;ALA A  41;LYS A  43;VAL A  74;LEU A  92;GLY A  96;LEU A 143","ADP A 301 ( 4.0A);ADP A 301 (-3.5A);ADP A 301 (-2.7A);None;ADP A 301 ( 4.8A);None;ADP A 301 (-4.7A)","0.84A","3aoxA-5hu3A:24.2","3aoxA-5hu3A:26.06"],["3AOX_A_EMHA901_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 718;ALA A 743;LYS A 745;LEU A 792;MET A 793;GLY A 796;LEU A 844","6HJ A1101 ( 4.6A);6HJ A1101 (-3.1A);6HJ A1101 (-4.2A);6HJ A1101 ( 4.9A);None;6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A)","0.39A","3aoxA-5j9zA:31.6","3aoxA-5j9zA:31.34"],["3AOX_A_EMHA901_1","5jzn","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE DCLK1","PF00069(Pkinase)",7,"ARG A 394;ALA A 417;LYS A 419;VAL A 449;LEU A 467;GLY A 471;LEU A 518","None;GUI A 701 ( 3.9A);GUI A 701 (-3.1A);None;GUI A 701 ( 4.7A);GUI A 701 (-3.6A);GUI A 701 (-4.4A)","0.68A","3aoxA-5jznA:22.5","3aoxA-5jznA:26.02"],["3AOX_A_EMHA901_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"ALA A 909;LYS A 911;VAL A 940;MET A 959;GLY A 962;LEU A1016","ATP A1200 (-3.5A);ATP A1200 (-3.8A);None;None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A)","0.54A","3aoxA-5lpyA:22.6","3aoxA-5lpyA:27.07"],["3AOX_A_EMHA901_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"ALA A 909;LYS A 911;VAL A 940;MET A 959;GLY A 962;LEU A1016","ADP A1200 (-3.5A);ADP A1200 ( 4.3A);None;None;ADP A1200 ( 4.0A);ADP A1200 (-4.7A)","0.54A","3aoxA-5lpzA:22.6","3aoxA-5lpzA:26.68"],["3AOX_A_EMHA901_1","5td2","Homo sapiens","TYROSINE-PROTEIN KINASE MER","PF07714(Pkinase_Tyr)",6,"LEU A 593;ALA A 617;LYS A 619;LEU A 671;MET A 674;GLY A 677","7AE A1000 ( 3.9A);7AE A1000 (-3.3A);7AE A1000 (-3.1A);7AE A1000 (-3.7A);None;7AE A1000 ( 3.7A)","0.47A","3aoxA-5td2A:11.8","3aoxA-5td2A:35.86"],["3AOX_A_EMHA901_1","5u6b","Homo sapiens","TYROSINE-PROTEIN KINASE RECEPTOR UFO","PF07714(Pkinase_Tyr)",6,"LEU A 542;ALA A 565;LYS A 567;LEU A 620;MET A 623;GLY A 626","7YS A9001 (-4.1A);7YS A9001 (-3.3A);None;7YS A9001 (-4.2A);7YS A9001 (-4.7A);7YS A9001 (-3.4A)","0.68A","3aoxA-5u6bA:29.5","3aoxA-5u6bA:38.46"],["3AOX_A_EMHA901_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",6,"ALA A 119;LYS A 121;VAL A 153;MET A 172;GLY A 175;LEU A 221","None","0.61A","3aoxA-5u7qA:19.8","3aoxA-5u7qA:25.12"],["3AOX_A_EMHA901_1","5uuu","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00615(RGS)",8,"ALA A 218;LYS A 220;VAL A 255;LEU A 271;LEU A 273;MET A 274;GLY A 277;LEU A 324","QRW A 601 (-3.4A);QRW A 601 (-3.0A);None;QRW A 601 ( 4.9A);None;MES A 604 (-3.9A);None;None","0.70A","3aoxA-5uuuA:21.8","3aoxA-5uuuA:21.56"],["3AOX_A_EMHA901_1","5uuu","Homo sapiens","BETA-ADRENERGIC RECEPTOR KINASE 1","PF00069(Pkinase);PF00615(RGS)",7,"ALA A 218;VAL A 255;LEU A 271;LEU A 273;MET A 274;GLY A 276;LEU A 324","QRW A 601 (-3.4A);None;QRW A 601 ( 4.9A);None;MES A 604 (-3.9A);None;None","0.97A","3aoxA-5uuuA:21.8","3aoxA-5uuuA:21.56"],["3AOX_A_EMHA901_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",6,"LEU A  24;ALA A  45;LYS A  47;MET A  98;GLY A 101;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 (-3.3A);9WS A 401 (-3.3A);None;9WS A 401 ( 4.3A);9WS A 401 (-4.6A)","0.69A","3aoxA-5w5jA:10.0","3aoxA-5w5jA:27.08"],["3AOX_A_EMHA901_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",6,"LEU A  33;ALA A  54;LYS A  56;VAL A  83;GLY A 105;LEU A 153","ANP A 501 ( 3.8A);ANP A 501 ( 3.7A);ANP A 501 (-2.4A);None;ANP A 501 ( 4.0A);ANP A 501 (-4.6A)","0.83A","3aoxA-6ao5A:7.7","3aoxA-6ao5A:24.04"],["3AOX_A_EMHA901_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",6,"ALA A 192;LYS A 194;VAL A 249;LEU A 269;GLY A 273;LEU A 319","BI9 A 501 (-3.3A);NH4 A 506 ( 4.4A);None;BI9 A 501 (-4.4A);BI9 A 501 (-3.3A);BI9 A 501 (-4.7A)","0.48A","3aoxA-6bqlA:22.3","3aoxA-6bqlA:13.41"],["3AOX_A_EMHA901_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"ARG A 879;LEU A 881;ALA A 906;LYS A 908;VAL A 938;GLY A 962;LEU A1010","None;ADP A1201 ( 4.5A);ADP A1201 (-3.4A);ADP A1201 (-2.8A);None;ADP A1201 ( 4.1A);ADP A1201 (-4.5A)","0.76A","3aoxA-6c7yA:27.8","3aoxA-6c7yA:15.03"],["3AOX_A_EMHA901_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",6,"ALA A 155;LYS A 157;VAL A 212;LEU A 232;GLY A 236;LEU A 282","H1N A 501 (-3.4A);H1N A 501 (-2.8A);H1N A 501 (-4.9A);H1N A 501 (-4.3A);H1N A 501 (-3.6A);H1N A 501 (-4.8A)","0.55A","3aoxA-6ccfA:22.0","3aoxA-6ccfA:13.95"],["3AOX_A_EMHA901_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",7,"ARG A 195;LEU A 197;ALA A 217;LEU A 266;MET A 267;GLY A 270;LEU A 319","None;FKY A9001 (-4.1A);FKY A9001 (-3.3A);FKY A9001 (-4.4A);None;FKY A9001 (-3.3A);FKY A9001 ( 4.9A)","0.83A","3aoxA-6cz4A:29.0","3aoxA-6cz4A:16.96"]]